Using next-generation sequencing (NGS) for microRNA (miRNA) and synthetic neurotransmission, we observed that large dense-core vesicles (LDCVs) contain a variety of miRNA together with classical neurotransmitters, and that miRNA can be released by vesicle fusion mediated by SNARE.
the model system for LDCVs 21 . LDCVs and synaptic vesicles share the conserved fusion machinery; i.e., soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins and Ca 2+ sensor synaptotagmin-1 that mediates Ca 2+ -dependent exocytosis 22 .
To study miRNA exocytosis by vesicle fusion, we focus on LDCVs because of their large size, high yield, and high purity. We purified LDCVs (95% purity) from bovine chromaffin cells, then used next-generation sequencing (NGS) to sequence miRNAs stored in LDCVs. Synthetic neurotransmission, the in-vitro reconstitution of vesicle fusion, supported the hypothesis that miRNA exocytosis is mediated by SNARE proteins and accelerated by Ca 2+ . These results suggest that miRNAs may be neuromodulators stored in vesicles and released by vesicle fusion along with classical neurotransmitters.
Results
We have established the LDCV purification technique based on continuous sucrose gradients using bovine adrenal medulla as described before 23, 24 . Vesicle proteins are highly enriched, whereas other contaminants are mostly removed 23 . Mitochondria, late, lysosomes, early endosomes, endoplasmic reticulum, proteasomes, and peroxisomes are not detected in LDCV samples 23 . This purification process yields primarily mature LDCVs with 100 ~ 200 nm in diameter 23 ; i.e., immature LDCVs (a marker, VAMP-4) are mostly removed.
We confirmed the enrichment of LDCVs by western blotting showing that LDCVs are highly enriched in vesicle membrane proteins (synaptotagmin-1 and synaptobrevin-2/VAMP-2), whereas exosomes and multivesicular bodies (a marker, LAMP-1) are removed during purification. (Supplementary Fig. 1 ). Proteomic profiling of exosomes 25 and western blotting data 26 reveal that exosomes are enriched with LAMP-1. Thus, our data support that miRNA-containing organelles are excluded.
To quantify the LDCV purity, we performed an overlay assay ( Fig. 1a-d) in which LDCVs were immobilized on a poly-L-lysine-coated glass slides, then immunostained with an antibody against synaptobrevin-2/VAMP-2 (a marker for LDCVs, green) and DiI (a lipophilic membrane dye, red). Overlaps (yellow) in an overlay assay indicate LDCVs, whereas contaminants stain red; note that mitochondria could be minorly included in LDCV samples 23 . An overlay assay shows 95% purity of LDCVs (119 LDCVs from 125 samples, Fig. 1d ). Size distribution of purified LDCVs with average of 135 nm determined by dynamic light scattering ( Fig. 1e ) correlate with electron microscopy data previously reported 23 .
Next, total RNAs were extracted from purified LDCVs by using miRNeasy Mini Kit (Qiagen). The RNAs stored in LDCVs were < 100 nucleotides (nt) long ( Fig. 2a) ; rRNA was not detected, although it constitutes ~80% of the total RNA in a cell, suggesting that LDCVs are specifically enriched with small RNAs. The small RNA libraries (Supplementary Fig. 2) were read using small RNA-sequencing (RNA-seq) technique with Illumina Hiseq 2500 platform. Surprisingly, the RNA library provides evidence for miRNA fraction at the peak with 141 bp; miRNAs of 20 ~ 24 nt are conjugated to ~120 bp of adapter ( Supplementary  Fig. 2) . miRNA fraction constitutes ~61% of RNAs extracted from LDCVs; i.e., miRNAs are selectively accumulated in LDCVs (Fig. 2b) . Size selection of miRNA fraction was applied for miRNA sequencing and we found a variety of miRNAs including 459 of known miRNAs and 315 of novel miRNAs predicted by miRDeep2 analysis tool ( Fig. 2c) (Supplementary   File 1,2) . However, most of the known miRNAs were expressed at low level less than 10 (on a log 2 scale) of library size normalized Count Per Million (CPM) (Fig. 2d) . Therefore, we used a criterion of 1,000 CPM (9.96 on a log 2 scale) to categorize miRNAs as high (69 miRNAs, 16.2%) and low (356 miRNAs, 83.8%) level miRNA ( Fig. 2e,f) . Intriguingly, the 69 high level miRNAs ( Fig. 2e ) comprise 94.8% of total mapped read counts (Fig. 2f) ; i.e., only a few miRNAs are highly expressed in LDCVs. miR-375 was the most abundant miRNA in LDCVs (28.9% of total mapped read counts, Fig.2g ). The most abundant miRNAs (top 5%; 21 miRNAs among 425 total miRNAs) stored in LDCVs account for 80% of CPM (Table 1) . We confirmed the reproducibility of RNA-seq data by using technical and biological replicate which are highly correlated (r=0.99, p<0.05) ( Supplementary Fig. 3) .
These data provide evidence that miRNAs including miR-375 are highly enriched in LDCVs.
Can miRNAs stored in LDCVs be released to extracellular fluid? We attempted to confirm miRNA exocytosis by using the reconstitution system of vesicle fusion called synthetic neurotransmission. We used purified LDCVs for synthetic neurotransmission and prepared plasma membrane-mimicking liposomes that contain the stabilized Q-SNARE complex (Online Methods). Liposomes also incorporated GelGreen dye, a water-soluble and membrane-impermeable green fluorescent nucleic acid dye. As a content-mixing assay, miRNAs stored in LDCVs bind to GelGreen after LDCV fusion, thereby increasing fluorescence of GelGreen ( Fig. 3a) . Indeed, we observed miRNA exocytosis mediated by SNARE assembly, because soluble VAMP-2 or no SNARE proteins in plasma membranemimicking liposomes completely inhibited miRNA exocytosis (Fig. 3b) . 100 μM Ca 2+ accelerated miRNA exocytosis that resulted from the activity of synaptotagmin-1, a Ca 2+ sensor, for vesicle fusion (Fig. 3b, Supplementary Fig. 4) . To further validate that miR-375 can be released from cells in response to stimulation, we used PC12 cell, the cell line derived from a pheochromocytoma of chromaffin cells. Indeed, stimulation of PC12 cells with 50 mM KCl that evokes membrane depolarization and Ca 2+ influx increased the level of miR-7 physiological conditions. Next, we quantified the copy number of miR-375 per LDCV ( Fig. 4a,b) . The number of LDCV particles was measured using Nanoparticle Tracking Analysis (NTA). To determine the copy number of miR-375, which is the most abundant miRNA in LDCVs, we used quantitative real-time PCR (qRT-PCR) to quantify miR-375. A synthesized Caenorhabditis elegans microRNA (cel-miR-39) as the spike-in control was added to normalize the RNA extraction efficiency. Using the data derived from the above experiments, we analyzed the relative ratio of miR-375 to LDCVs for each sample. Each LDCV contained approximately 400 ~ 500 miR-375 ( Fig. 4b) , suggesting that LDCVs contain much higher number of miRNAs than other miRNA-containing organelles such as exosomes 11 .
Can miR-375 be a contaminant from the cytosol, which is adsorbed to the outside of LDCVs during purification procedure? Next, we assessed the possibility that miR-375 could attach to vesicle membranes during the purification process as an artefact (Fig. 4c,d) . To confirm that miR-375 is really stored inside LDCVs, we applied RNase A, because RNase A selectively degrades vesicle-free miRNA, but not vesicle-incorporated miRNA. Indeed, RNase A degraded cel-miR-39, which was mixed with LDCVs prior to RNase A, whereas miR-375 was intact ( Fig. 4d) , indicating that miR-375 is incorporated in LDCVs. Taken together, our data suggest that miR-375 is stored in LDCVs (~500 copies) and miRNA exocytosis is mediated by SNARE assembly and accelerated by Ca 2+ stimulus.
Finally, we tested the specificity of miR-375 by investigating whether miR-375 is present in synaptic vesicles purified from mice brains ( Fig. 4e) . Surprisingly, we found that miR-375 is only stored in LDCVs, but not in synaptic vesicles, supporting the specificity of miR-375. Altogether, these data provide evidence that miR-375 is not an artefact or a byproduct caused by vesicle purification procedure, but miR-375 might be a novel neuromodulator stored in LDCVs and released by vesicle fusion in response to stimulation.
Discussion
Our data strongly suggest that miRNAs are stored in vesicles and can be released along with classical neurotransmitters by vesicle fusion. LDCVs contain non-coding RNA (ncRNA) together with catecholamines. Exosomes also carry ncRNAs, but up to 90% of these are rRNAs and miRNAs are less than 5% 27 . Furthermore, abundant miRNAs are present at less than one copy per exosome 11 . In comparison with exosomes, the variety of miRNAs is highly enriched in LDCVs excluding other types of ncRNA such as rRNAs and tRNAs. These observation suggests that LDCVs may be specific cargos and carriers in neurons and neuroendocrine cells that deliver miRNAs to extracellular fluid.
The average diameter of LDCVs is 167.7 nm 23 , with inner radius of 80 nm, which corresponds to 2.14 × 10 -18 liter. Therefore, 400 ∼ 500 copies of miR-375 in a single LDCV is a concentration of 320 ∼ 400 μM. LDCV in chromaffin cells contains ∼2.5 × 10 6 catecholamine molecules per vesicle 28 and a variety of neuropeptides; e.g., ∼430
neuropeptide Y (NPY) molecules 21, 29 . Therefore, the observed miRNA concentration is comparable to the number of other neuropeptides in LDCVs, proposing that miRNAs might be novel neuromodulators or hormones that are stored in LDCVs and released together with catecholamines and neuropeptides ( Fig. 5) . Therefore, we propose a new function of noncoding RNAs named 'ribomone (ribonucleotide + hormone)' that are stored inside the vesicles and released by active vesicle fusion in response to stimulation, thereby regulating cell−to−cell communication including gene silencing and cellular signaling. Extracellular circulating miRNAs have been detected in serum, so they might be biomarkers of diseases 10, 30, 31 . Most studies have proposed that extracellular miRNAs can be packaged into membrane-associated organelles such as exosomes, microvesicles, and extracellular vesicles 10,32 , but the mechanisms and origins of vesicle-free extracellular miRNAs remain unclear. To our knowledge, our data are the first to identify miRNA exocytosis by LDCV fusion. LDCVs in chromaffin cells, which are neuroendocrine and modified sympathetic ganglion cells, mainly contain catecholamines 33 . Upon activation of the sympathetic nervous system, catecholamines released by LDCV fusion spread through the bloodstream, thereby mediating stress and the 'fight-or-flight' physiological response 33 . Therefore, fusion of LDCVs could result in a high level of vesicle-free miRNAs together with catecholamines in blood. miR-375 is the most abundant miRNA in LDCVs (~30% of total miRNA read counts); it is highly expressed in the pancreatic islets 34 and motor neurons 35 , where it regulates neuronal development 36 . miR-375 is also detected in plasma and serum as a circulating miRNA, and may be a biomarker for diabetes 37 , hepatocellular carcinoma 38 , and Alzheimer`s disease 39 . Despite intense study of miR-375, the physiological roles and origin of circulating extracellular miR-375 are still not understood. Our data support the hypothesis that LDCVs in chromaffin cell may be one source of circulating miR-375, but its function remains to be elucidated in both normal physiological and pathological conditions. Extracellular miRNAs could be transported by endocytosis into the target cells, where they regulate gene expression, but the identity of the target cells and the mechanisms of endocytosis are not fully understood. Secondly, miRNA clearly regulates gene expression inside the cell, but we hypothesize that extracellular miRNAs may directly regulate receptor activity as an agonist or antagonist, similarly to aptamers, which are oligonucleotides that bind to a specific target, in a manner that differs from the way in which it regulates gene 1 0 signaling 17 . So far, little is known about the signaling mechanism by which extracellular miRNAs can regulate receptors and ion channels. Thirdly, the mechanism by which miRNAs are transported into vesicles is not known. Considering that some miRNAs (e.g., miR-375) are selectively and specifically accumulated in LDCVs, LDCVs could have a carrier or transporter for miRNA uptake. LDCVs express nucleotide transporters 44 , but the activity of RNA uptake has never been studied. Fourthly, ribonucleases in the extracellular could degrade vesicle-free extracellular miRNAs. High-density lipoproteins (HDL) 12 or Argonaute2 13 might protect extracellular miRNAs from cleavage by ribonucleases. We have the mass spectrometry data showing that RNA-binding proteins such as hnRNPs and apolipoprotein A-I are detected in LDCVs whereas Argonaute2 is not (unpublished data).
Further work will be required to identify miRNA-binding proteins that control the miRNA stability and miRNA function in LDCVs. 
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